MicroRNA in Alzheimer's disease revisited: implications for major neuropathological mechanisms

Reihaneh Dehghani1, Farzaneh Rahmani2, Nima Rezaei1

  • 1Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran 1419783151, Iran.

Reviews in the Neurosciences
|September 24, 2017
PubMed

Insights

Alzheimer's disease involves more than amyloid plaques. MicroRNAs (miRNAs) are implicated in various AD pathomechanisms, including tau pathology, lipid metabolism, and neuroinflammation, offering new insights into disease progression.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Alzheimer's disease (AD) pathology extends beyond amyloid-beta (Aβ) plaques, involving tau hyper-phosphorylation, lipid dysregulation, and neuroinflammation.
  • Aberrant protein processing, cellular stress (mitochondrial, apoptotic), synaptic dysfunction, and impaired neural plasticity are key contributors to AD pathogenesis.
  • MicroRNAs (miRNAs) are increasingly recognized for their role in regulating gene expression and their involvement in AD.

Purpose of the Study:

  • To investigate the precise pathomechanisms of Alzheimer's disease where microRNAs (miRNAs) play a significant role.
  • To elucidate how dysregulated miRNAs impact common pathways and abnormal mechanisms in the AD brain.

Main Methods:

  • Literature search conducted on PubMed and Scopus databases.
  • Search terms included 'Alzheimer Disease' OR 'Alzheimer's Disease' AND 'microRNAs' OR 'miRNA' OR 'MiR'.
  • Analysis focused on identifying and summarizing the role of miRNAs in AD pathomechanisms.

Main Results:

  • A limited number of common dysregulated pathways are affected by various miRNAs in the AD brain.
  • miRNAs are implicated in key AD pathologies such as Aβ and tau accumulation, lipid metabolism, neuroinflammation, and cellular stress.
  • Specific miRNAs modulate neural membrane characteristics, blood-brain barrier transport, and the CNS oxidative balance.

Conclusions:

  • MicroRNAs are critical regulators involved in multiple facets of Alzheimer's disease pathology.
  • Understanding miRNA dysregulation offers potential therapeutic targets for AD.
  • Further research into miRNA-mediated mechanisms is crucial for developing effective AD treatments.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K